NeuroOne's Distribution Agreement Enhancement
License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS Markets
Agreement expected to boost NeuroOne sales revenue and profitability.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a pioneer in medical technology focused on enhancing surgical solutions for neurological disorders, has announced a significant enhancement to its distribution agreement with Zimmer Biomet. This modification grants Zimmer Biomet exclusive rights to distribute the groundbreaking OneRF Ablation System for brain applications.
This agreement involves an upfront payment of $3 million to NeuroOne, potentially supplemented by additional milestone payments contingent on performance metrics. The company anticipates this collaboration will generate considerable revenue and improve profitability, aligning with its strategic vision of growth.
What is the OneRF Ablation System?
The OneRF Ablation System holds the distinction of being the only FDA-cleared radiofrequency ablation device in the United States, designed for both diagnostic and therapeutic applications. Initially launched in April, the system has already demonstrated success in several ablation cases, effectively identifying and targeting brain tissue responsible for seizure activity. By accomplishing this, the device has the capability to significantly diminish or even eradicate brain-related seizures.
Moreover, this technology promises to minimize hospital stays, reduce the number of required surgeries, and lower adverse event rates, thereby enhancing patient safety. The innovative aspects of the OneRF system allow it to be utilized at the bedside, dramatically cutting operational costs and facilitating a streamlined process for diagnosis and treatment within a single hospital visit.
Leadership Insights on the Expansion
Dave Rosa, president and CEO of NeuroOne, expressed his enthusiasm regarding the expanded agreement with Zimmer Biomet. He asserted, “This partnership is a pivotal catalyst for our growth trajectory. Leveraging Zimmer Biomet’s extensive reach in robotic technology and distribution networks in the U.S. and globally will enhance our operational capabilities.”
He reinforced the distinction of the OneRF as the world’s first FDA-cleared system suitable for both diagnostic and therapeutic uses, highlighting its competitive edge over traditional electrode technologies.
Zimmer Biomet's Perspective
Brian Hatcher, President of SET and CMFT at Zimmer Biomet, echoed the sentiment shared by NeuroOne, stating, “We are excited to broaden our collaboration to encompass the OneRF Ablation System. This builds upon our existing agreement that covers NeuroOne's Cortical and sEEG diagnostic electrode technology, and we are eager to introduce this innovation to the market shortly.”
About NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation stands at the forefront of developing minimally invasive, high-definition solutions tailored for EEG recording, brain stimulation, and ablation techniques. Catering to patients with various neurological disorders such as epilepsy, Parkinson's disease, and persistent pain, the company is dedicated to advancing patient outcomes while reducing procedural expenses.
Future prospects include exploring applications in areas such as mood disorders, high blood pressure, and innovations in artificial intelligence in healthcare. The company’s evolving portfolio reflects its commitment to making strides in neurological health.
You can learn more about our mission and innovations by visiting www.nmtc1.com.
Frequently Asked Questions
What does the expanded agreement with Zimmer Biomet entail?
The agreement permits Zimmer Biomet exclusive rights to distribute the OneRF Ablation System, enhancing NeuroOne's market presence.
What is the significance of the OneRF Ablation System?
The OneRF Ablation System is FDA-cleared for both diagnostic and therapeutic uses, representing a major advancement in treating neurological disorders.
How does the OneRF System improve patient outcomes?
It minimizes hospital stays, reduces surgeries, and enhances patient safety while streamlining the diagnosis and treatment process.
What is NeuroOne's focus as a company?
NeuroOne is committed to providing innovative, minimally invasive solutions for various neurological conditions to enhance patient care.
Where can I find more information about NeuroOne?
Further information about NeuroOne’s innovations can be found at their official website: www.nmtc1.com.
